Starpharma Pty Limited

Biomolecular Research Institute Ltd.

Ilexus Pty Limited

Prana Biotechnology Limited

Starpharma Limited

Barry Ross Matthews

George Holan

Jonathan Bayldon Baell

Geoffrey Alan Pietersz

Thomas P J Garrett

P Mark Hogarth

Thomas D McCarthy

David Francis O'Keefe

Peter Karellas

Scott Andrew Henderson

Thomas David McCarthy

Kevin Jeffrey Barnham

Ian F C McKenzie

Robert Cherny

Kelly F Maxwell

Vidana Epa

Maree S Powell

Susanne Pallich

David Francis O'keefe

Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.

Agent for the prevention and treatment of sexually transmitted diseases-I

The present invention relates to compounds which inhibit the binding of metal ions to a region in the N-terminal loop of the &#x3b2;-amyloid peptide which includes a cluster of histidine residues. In addition, the invention relates to pharmaceutical compositions including these compounds as the active agent, and to methods of treatment involving the administration of these compounds. The compounds of the invention are useful in the treatment of Alzheimer's Disease and other amyloid-related conditions. In a first aspect the present invention provides a compound which interacts with the &#x3b2;-amyloid peptide in such a way that the N-terminal loop of the peptide (amino acid residues 1-15) is blocked or destabilised, thereby inhibiting the binding of one or more metal ions to at least one histidine residue within the N-terminal loop. Preferably the compound inhibits binding of Cu, Znand Feions, but not Mgor Caions.

&#x3b2;-amyloid peptide inhibitors

To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.

Anionic or cationic dendrimer antimicrobial or antiparasitic compositions

This invention relates to a method of inhibiting Fc receptor binding of immunoglobulin including the use of a Fc receptor modulating compound which binds to defined surfaces on a Fc receptor. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.

Fc receptor modulators and uses thereof

Methods for inhibiting Fc receptor binding of immunoglobulin in a patient comprising administering pharmaceutical compositions comprising Fc modulating compounds are disclosed.

An antiviral compound comprises a linear non-carbohydrate polymer having a plurality of side chain groups, wherein at least one of the side chain groups has an anionic- or cationic-containing moiety bonded or linked thereto.

Antiviral linear polymers

To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing. moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.

Anionic or cationic dendrimer antimicrobial or autiprotozoan compositions

For proposes of prophylactic or treatment of diseases related to inappropriate angiogenesis, a compound can be administered that is (i) a linear, non-carbohydrate polymer having a plurality of side chain groups or (ii) a dendrimer having a plurality of terminal groups. At least one of the side chain groups of the linear, non-carbohydrate polymer has an anionic- or cationic-containing moiety bonded or linked thereto. The plurality of terminal groups of the dendrimer has at least one anionic- or cationic-containing moiety bonded or linked thereto.

Angiogenic inhibitory compounds

This invention relates to a pharmaceutical composition comprising a Fc receptor modulating compound and a pharmaceutically acceptable carrier. The present invention also relates to a method for treating a variety of diseases using a Fc receptor modulating compound.

An antiviral compound comprises a dendrimer such as a polyamidoamine or polyly sine dendrimer having a plurality of terminal groups, wherein at least one of the terminal groups has an anionic- or cationic-containing moiety bonded thereto, particularly a sulfonic acid-containing, carboxylic acid-containing or trimethylammonium-containing moiety or the like.

Growing community of inventors

Olinda, Australia

Barry Ross Matthews